DBD vs PLUS

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 11, 2026

DBD

53.4
AI Score
VS
PLUS Wins

PLUS

55.2
AI Score

Investment Advisor Scores

DBD

53score
Recommendation
HOLD

PLUS

55score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric DBD PLUS Winner
Revenue 2.82B 1.32B DBD
Net Income 27.10M 70.66M PLUS
Gross Margin 24.8% 25.2% PLUS
Net Margin 1.0% 5.4% PLUS
Operating Income 128.80M 95.36M DBD
ROE 2.9% 6.4% PLUS
ROA 0.7% 3.5% PLUS
Total Assets 3.66B 2.00B DBD
Current Ratio 1.27 1.99 PLUS

Relative Price Performance (Last 90 Days)

DBD 1M: -9.4% · 3M: -20.1% PLUS 1M: +1.8% · 3M: +8.9%

Current Technical Phase

DBD

Markdown
Sell / avoid

Price below a falling SMA50 (slope -4.9%), weak momentum, RSI 38

RSI (14): 38.3 · Price: $57.34

PLUS

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (2.1% over 20 days), RSI 56

RSI (14): 56.4 · Price: $96.61

Fundamentals Snapshot

Metric DBD PLUS
Market Cap — —
Forward P/E 9.3 17.4
Trailing P/E 28.5 19.8
Revenue (TTM) — —
Revenue Growth 0.1% 0.1%
Gross Margin 0.3% 0.3%
Operating Margin 0.1% 0.1%
EPS 2.11 4.77
Dividend Yield — 0.01%

Frequently Asked Questions

Based on our detailed analysis, PLUS is currently the stronger investment candidate, winning 6 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.